IS4161A - Aðferð til að útbúa ljósfræðilega hrein Na+, Mg2+, Li+, K+ eða Ca2+ sölt (-)-5-metoxý-2-[[(4-metoxý-3,5-dímetýl-2-pýridínýl)metýl]súlfinýl]-1H-bensimídasóls og milliefnasamband. - Google Patents

Aðferð til að útbúa ljósfræðilega hrein Na+, Mg2+, Li+, K+ eða Ca2+ sölt (-)-5-metoxý-2-[[(4-metoxý-3,5-dímetýl-2-pýridínýl)metýl]súlfinýl]-1H-bensimídasóls og milliefnasamband.

Info

Publication number
IS4161A
IS4161A IS4161A IS4161A IS4161A IS 4161 A IS4161 A IS 4161A IS 4161 A IS4161 A IS 4161A IS 4161 A IS4161 A IS 4161A IS 4161 A IS4161 A IS 4161A
Authority
IS
Iceland
Prior art keywords
methoxy
sulfinyl
benzimidazole
pyridinyl
dimethyl
Prior art date
Application number
IS4161A
Other languages
English (en)
Other versions
IS1854B (is
Inventor
Lennart Lindberg Per
Von Unge Sverker
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20390088&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS4161(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IS4161A publication Critical patent/IS4161A/is
Publication of IS1854B publication Critical patent/IS1854B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Preventing Corrosion Or Incrustation Of Metals (AREA)
IS4161A 1993-05-28 1994-05-06 Aðferð til að útbúa ljósfræðilega hrein Na+, Mg2+, Li+, K+ eða Ca2+ sölt (-)-5-metoxý-2-[[(4-metoxý-3,5-dímetýl-2-pýridínýl)metýl]súlfinýl]-1H-bensimídasóls og milliefnasamband. IS1854B (is)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE19939301830A SE9301830D0 (sv) 1993-05-28 1993-05-28 New compounds

Publications (2)

Publication Number Publication Date
IS4161A true IS4161A (is) 1994-11-29
IS1854B IS1854B (is) 2003-02-21

Family

ID=20390088

Family Applications (1)

Application Number Title Priority Date Filing Date
IS4161A IS1854B (is) 1993-05-28 1994-05-06 Aðferð til að útbúa ljósfræðilega hrein Na+, Mg2+, Li+, K+ eða Ca2+ sölt (-)-5-metoxý-2-[[(4-metoxý-3,5-dímetýl-2-pýridínýl)metýl]súlfinýl]-1H-bensimídasóls og milliefnasamband.

Country Status (43)

Country Link
US (5) US5693818A (is)
EP (3) EP1020460B1 (is)
JP (3) JP3549111B2 (is)
KR (1) KR100337274B1 (is)
CN (2) CN1055469C (is)
AT (1) ATE197452T1 (is)
CA (2) CA2337581A1 (is)
CL (1) CL2009000805A1 (is)
CY (1) CY2224B1 (is)
CZ (1) CZ287876B6 (is)
DE (4) DE69435220D1 (is)
DK (3) DK1020460T3 (is)
DZ (1) DZ1785A1 (is)
EE (1) EE03157B1 (is)
ES (3) ES2099047T3 (is)
FI (2) FI117755B (is)
GR (2) GR970300012T1 (is)
HK (3) HK1008330A1 (is)
HR (1) HRP940307B1 (is)
HU (1) HU226824B1 (is)
IL (1) IL109684A (is)
IS (1) IS1854B (is)
LT (1) LT3287B (is)
LU (1) LU91870I2 (is)
LV (1) LV11034B (is)
MA (1) MA23210A1 (is)
MY (1) MY121192A (is)
NO (2) NO307378B1 (is)
NZ (1) NZ266915A (is)
PL (1) PL178994B1 (is)
PT (3) PT1020461E (is)
RU (1) RU2137766C1 (is)
SA (2) SA05260103B1 (is)
SE (1) SE9301830D0 (is)
SG (1) SG49283A1 (is)
SI (2) SI9420002B (is)
SK (1) SK282524B6 (is)
TN (1) TNSN94058A1 (is)
TW (1) TW389761B (is)
UA (1) UA60289C2 (is)
WO (1) WO1994027988A1 (is)
YU (1) YU49065B (is)
ZA (1) ZA943557B (is)

Families Citing this family (209)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
US5877192A (en) * 1993-05-28 1999-03-02 Astra Aktiebolag Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole
US6875872B1 (en) * 1993-05-28 2005-04-05 Astrazeneca Compounds
EP0723436B1 (en) * 1994-07-08 2001-09-26 AstraZeneca AB Multiple unit tableted dosage form i
SE504459C2 (sv) * 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
SE9500422D0 (sv) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
SE9500478D0 (sv) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
HRP960232A2 (en) * 1995-07-03 1998-02-28 Astra Ab A process for the optical purification of compounds
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6699885B2 (en) 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
SE508669C2 (sv) * 1996-04-26 1998-10-26 Astra Ab Nytt förfarande
SE510666C2 (sv) * 1996-12-20 1999-06-14 Astra Ab Nya Kristallmodifikationer
SE9702000D0 (sv) * 1997-05-28 1997-05-28 Astra Ab New pharmaceutical formulation
SE510650C2 (sv) 1997-05-30 1999-06-14 Astra Ab Ny förening
US6747155B2 (en) 1997-05-30 2004-06-08 Astrazeneca Ab Process
SE510643C2 (sv) * 1997-06-27 1999-06-14 Astra Ab Termodynamiskt stabil omeprazol natrium form B
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6174548B1 (en) 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
JP4546643B2 (ja) * 1997-12-08 2010-09-15 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 酸不安定な活性化合物を含有する新規の坐剤形
SE9704869D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulaton II
SE9704870D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
WO1999053918A1 (fr) * 1998-04-20 1999-10-28 Eisai Co., Ltd. Compositions stabilisees contenant des composes du type benzimidazole
CN100396675C (zh) 1998-08-10 2008-06-25 加利福尼亚州大学董事会 质子泵抑制剂的前药
US6733778B1 (en) 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
SE9803772D0 (sv) 1998-11-05 1998-11-05 Astra Ab Pharmaceutical formulation
IL142629A0 (en) 1998-11-18 2002-03-10 Astra Ab Improved chemical process and pharmaceutical formulation
SE9900274D0 (sv) 1999-01-28 1999-01-28 Astra Ab New compound
US6852739B1 (en) * 1999-02-26 2005-02-08 Nitromed Inc. Methods using proton pump inhibitors and nitric oxide donors
TWI243672B (en) 1999-06-01 2005-11-21 Astrazeneca Ab New use of compounds as antibacterial agents
EP1191948A2 (en) * 1999-06-11 2002-04-03 Neorx Corporation High dose radionuclide complexes for bone marrow suppression
US7094885B2 (en) * 1999-07-11 2006-08-22 Neorx Corporation Skeletal-targeted radiation to treat bone-associated pathologies
US6268385B1 (en) 1999-08-26 2001-07-31 Robert R. Whittle Dry blend pharmaceutical formulations
US6326384B1 (en) 1999-08-26 2001-12-04 Robert R. Whittle Dry blend pharmaceutical unit dosage form
US6312723B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Pharmaceutical unit dosage form
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
EP1595879A3 (en) * 1999-08-26 2010-01-27 aaiPharma Inc. Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6316020B1 (en) * 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
US6262085B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6780880B1 (en) * 1999-08-26 2004-08-24 Robert R. Whittle FT-Raman spectroscopic measurement
US6312712B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Method of improving bioavailability
US6262086B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Pharmaceutical unit dosage form
AU2878801A (en) * 1999-10-01 2001-05-10 Natco Pharma Limited An improved pharmaceutical composition and a process for its preparation
WO2001028559A1 (fr) * 1999-10-20 2001-04-26 Eisai Co., Ltd. Procede de stabilisation de composes benzimidazoles
SE9903831D0 (sv) 1999-10-22 1999-10-22 Astra Ab Formulation of substituted benzimidazoles
DK1257269T3 (da) 2000-02-24 2005-03-14 Kopran Res Lab Ltd Syrestabile benzimidazolderivater til oral indgivelse mod ulcus
SE0000774D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
US20030212274A1 (en) * 2000-05-15 2003-11-13 Bakthavathsalan Vijayaraghavan Novel amorphous form of omeprazole salts
US6306435B1 (en) * 2000-06-26 2001-10-23 Yung Shin Pharmaceutical Industrial Co. Ltd. Oral pharmaceutical preparation embedded in an oily matrix and methods of making the same
CA2386716C (en) * 2002-05-17 2012-07-24 Bernard Charles Sherman Magnesium salt of s-omeprazole
AU2003204233B8 (en) * 2000-08-04 2008-06-26 Bernard Charles Sherman Magnesium salt of S-omeprazole
CA2775616C (en) 2000-08-04 2013-09-17 Takeda Pharmaceutical Company Limited Salts of benzimidazole compound and application thereof
US6544556B1 (en) 2000-09-11 2003-04-08 Andrx Corporation Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
US20020064555A1 (en) * 2000-09-29 2002-05-30 Dan Cullen Proton pump inhibitor formulation
WO2002062398A2 (en) 2001-01-08 2002-08-15 Neorx Corporation Radioactively labelled conjugates of phosphonates
AU2002338655A1 (en) * 2001-04-13 2002-10-28 Aspinterm Llc Methods of preparing sulfinamide and sulfoxides
SE0101379D0 (sv) 2001-04-18 2001-04-18 Diabact Ab Komposition som hämmar utsöndring av magsyra
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
GB2376231A (en) * 2001-06-06 2002-12-11 Cipla Ltd Benzimidazole-cyclodextrin inclusion complex
SE0102993D0 (sv) 2001-09-07 2001-09-07 Astrazeneca Ab New self emulsifying drug delivery system
CA2445513A1 (en) 2001-09-18 2003-03-27 Zeria Pharmaceutical Co., Ltd. Benzimidazole derivatives
MXPA04007169A (es) * 2002-01-25 2004-10-29 Santarus Inc Suministro transmucosal de inhibidores de bomba de protones.
CA2474246C (en) * 2002-03-05 2010-06-29 Astrazeneca Ab Alkylammonium salts of omeprazole and esomeprazole
CA2480826C (fr) 2002-04-09 2012-02-07 Flamel Technologies Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
US6894066B2 (en) * 2002-05-09 2005-05-17 Bernard Charles Sherman Magnesium salt of S-omeprazole
US6897227B2 (en) * 2002-07-19 2005-05-24 Winston Pharmaceuticals, Inc. Prodrugs of proton pump inhibitors
TW200410955A (en) 2002-07-29 2004-07-01 Altana Pharma Ag Novel salt of (S)-PANTOPRAZOLE
US7211590B2 (en) * 2002-08-01 2007-05-01 Nitromed, Inc. Nitrosated proton pump inhibitors, compositions and methods of use
WO2004020436A1 (en) 2002-08-30 2004-03-11 Reddy's Laboratories Limited Amorphous hydrates of esomeprazole magnesium and process for the preparation thereof
AU2003273000A1 (en) 2002-10-16 2004-05-04 Takeda Pharmaceutical Company Limited Stable solid preparations
SE0203065D0 (sv) 2002-10-16 2002-10-16 Diabact Ab Gastric acid secretion inhibiting composition
EA200500673A1 (ru) 2002-10-22 2005-12-29 Рэнбакси Лабораториз Лимитед Аморфная форма соли эзомепразола, способ ее получения и фармацевтическая композиция на её основе
WO2004046134A2 (en) * 2002-11-18 2004-06-03 Dr. Reddy's Laboratories Limited Crystalline form ii of esomeprazole magnesium trihydrate and process for its preparation
DE10254167A1 (de) 2002-11-20 2004-06-09 Icon Genetics Ag Verfahren zur Kontrolle von zellulären Prozessen in Pflanzen
SI1575941T1 (sl) 2002-12-06 2012-08-31 Nycomed Gmbh Postopek za pripravo (S)-pantoprazola
US7452998B2 (en) 2002-12-06 2008-11-18 Nycomed Gmbh Process for preparing optically pure active compounds
FR2848555B1 (fr) 2002-12-16 2006-07-28 Negma Gild Enantiomere(-)du tenatoprazole et son application en therapeutique
US20040166162A1 (en) * 2003-01-24 2004-08-26 Robert Niecestro Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid
CA2517005A1 (en) * 2003-02-20 2004-09-02 Santarus, Inc. A novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
CN1777598A (zh) * 2003-02-28 2006-05-24 兰贝克赛实验室有限公司 S－奥美拉唑的多晶型物
WO2004089935A1 (en) * 2003-04-10 2004-10-21 Hetero Drugs Limitd Novel crystalline forms of s-omeprazole magnesium
CN1842525A (zh) * 2003-05-05 2006-10-04 兰贝克赛实验室有限公司 苯并咪唑衍生物的钡盐
WO2004099182A1 (en) * 2003-05-05 2004-11-18 Ranbaxy Laboratories Limited Zinc salt of (s)-omeprazole
NZ544173A (en) * 2003-07-15 2009-04-30 Alevium Pharmaceuticals Inc Process for preparing isomerically pure prodrugs of benzimidazole derivative proton pump inhibitors
WO2005007115A2 (en) * 2003-07-18 2005-01-27 Santarus, Inc. Pharmaceutical composition for inhibiting acid secretion
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
AR045061A1 (es) * 2003-07-18 2005-10-12 Santarus Inc Formulacion farmaceutica y metodo para tratar trastornos gastrointestinales causados por acido
CN100457104C (zh) * 2003-07-23 2009-02-04 尼科梅德有限责任公司 质子泵抑制剂的碱性盐
US20060189590A1 (en) * 2003-07-23 2006-08-24 Bernhard Kohl Alkaline salts of proton pump inhibitors
WO2005011637A1 (ja) * 2003-08-04 2005-02-10 Eisai Co., Ltd. 用時分散型製剤
SE0302382D0 (sv) * 2003-09-04 2003-09-04 Astrazeneca Ab New salts II
SE0302381D0 (sv) 2003-09-04 2003-09-04 Astrazeneca Ab New salts I
EP1663173A1 (en) * 2003-09-25 2006-06-07 Natco Pharma Limited Enteric soft gelatin capsule containing esomeprazole and method of preparation
ATE544447T1 (de) 2003-09-26 2012-02-15 Alza Corp Arzneistoffcoating mit hohem wirkstoffanteil sowie methoden zu dessen herstellung
US20050075371A1 (en) * 2003-10-03 2005-04-07 Allergan, Inc. Methods and compositions for the oral administration of prodrugs of proton pump inhibitors
WO2005034924A1 (en) * 2003-10-14 2005-04-21 Natco Pharma Limited Enteric coated pellets comprising esomeprazole, hard gelatin capsule containing them, and method of preparation
GB0403165D0 (en) * 2004-02-12 2004-03-17 Ct Novel uses for proton pump inhibitors
US20070161679A1 (en) * 2004-02-18 2007-07-12 Allergan, Inc. Method and compositions for the intravenous administration of compounds related to proton pump inhibitors
JP2007523163A (ja) * 2004-02-18 2007-08-16 アラーガン、インコーポレイテッド プロトンポンプインヒビターのプロドラッグの投与のための方法および組成物
SE0400410D0 (sv) 2004-02-20 2004-02-20 Astrazeneca Ab New compounds
WO2005082888A1 (en) * 2004-03-01 2005-09-09 Milen Merkez Ilac Endustrisi A.S. Process for the preparation of magnesium salt of omeprazole
WO2005105786A1 (en) 2004-04-28 2005-11-10 Hetero Drugs Limited A process for preparing pyridinylmethyl-1h- benzimidazole compounds in enantiomerically enriched form or as single enantiomers
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20050267159A1 (en) * 2004-05-28 2005-12-01 Aaipharma, Inc. Magnesium complexes of S-omeprazole
US20050267157A1 (en) * 2004-05-28 2005-12-01 David White Magnesium-S-omeprazole
DE602004025386D1 (de) * 2004-05-28 2010-03-18 Hetero Drugs Ltd Neue stereoselektive synthese von benzimidazolsulfoxiden
WO2006001755A1 (en) * 2004-06-24 2006-01-05 Astrazeneca Ab A new esomeprazole sodium salt crystal modification
WO2006001753A1 (en) * 2004-06-24 2006-01-05 Astrazeneca Ab New process for the preparation of crystal modifications for use in the preparation of esomeprazole sodium salt
US20060024362A1 (en) * 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
AU2005268056B2 (en) 2004-08-06 2008-07-31 Eisai R&D Management Co., Ltd. Salts of benzimidazole derivative with amines and process for production thereof
KR100847635B1 (ko) * 2004-08-06 2008-07-21 에자이 알앤드디 매니지먼트 가부시키가이샤 벤즈이미다졸 유도체와 아민과의 염
US8541026B2 (en) 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
WO2006066932A1 (en) * 2004-12-24 2006-06-29 Lek Pharmaceuticals D.D. Stable pharmaceutical composition comprising an active substance in the form of solid solution
US20060160783A1 (en) * 2004-12-30 2006-07-20 Transform Pharmaceuticals, Inc. Novel omeprazole forms and related methods
ES2259269B1 (es) 2005-03-03 2007-11-01 Esteve Quimica, S.A. Procedimiento para la preparacion de derivados de 2-(2-piridilmetilsulfinil)-bencimidazol opticamente activos.
JP4837722B2 (ja) 2005-03-25 2011-12-14 リブゾン ファーマシューティカル グループ インク． 置換スルホキシド化合物、その調製方法、およびその使用方法
EP1885711A1 (en) 2005-05-06 2008-02-13 Glenmark Pharmaceuticals Limited Esomeprazole strontium salt, process for its preparation and pharmaceutical compositions containing same
US8841333B2 (en) * 2005-05-09 2014-09-23 Takeda Pharmaceuticals U.S.A., Inc. Methods for treating nephrolithiasis
US7803817B2 (en) 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
US7981908B2 (en) 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
WO2006134605A1 (en) 2005-06-15 2006-12-21 Hetero Drugs Limited Amorphous esomeprazole hydrate
KR100641534B1 (ko) * 2005-07-28 2006-11-01 한미약품 주식회사 에스오메프라졸 및 그의 염의 제조방법
WO2007019153A2 (en) * 2005-08-03 2007-02-15 Tap Pharmaceutical Products, Inc. Methods for treating hypertension
US20070043085A1 (en) * 2005-08-19 2007-02-22 Glenmark Pharmaceuticals Limited Process for the preparation of amorphous form of neutral esomeprazole
WO2007031845A2 (en) * 2005-09-14 2007-03-22 Glenmark Pharmaceuticals Limited Polymorphic forms of (s)-omeprazole magnesium salts and processes for their preparation
CA2624179A1 (en) * 2005-10-06 2007-04-12 Auspex Pharmaceuticals, Inc. Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties
US7576219B2 (en) 2005-10-26 2009-08-18 Hanmi Pharm. Co., Ltd Crystalline S-omeprazole strontium hydrate, method for preparing same, and pharmaceutical composition containing same
AU2006323245B2 (en) 2005-12-05 2011-03-03 Astrazeneca Ab New process for the preparation of esomeprazole non-salt form
EP1801110A1 (en) 2005-12-22 2007-06-27 KRKA, tovarna zdravil, d.d., Novo mesto Esomeprazole arginine salt
US7553857B2 (en) 2005-12-23 2009-06-30 Lek Pharmaceuticals D.D. S-omeprazole magnesium
US7799925B2 (en) * 2005-12-28 2010-09-21 Unión Químico Farmacéutica, S.A. Process for the preparation of the (S)-enantiomer of omeprazole
US8063074B2 (en) * 2006-05-04 2011-11-22 Dr. Reddy's Laboratories Limited Polymorphic forms of esomeprazole sodium
DE602007010926D1 (de) * 2006-06-07 2011-01-13 Astrazeneca Ab Neues verfahren zur herstellung von ammoniumsalzen von esomeprazol
US7863330B2 (en) 2006-06-14 2011-01-04 Rottapharm S.P.A. Deloxiglumide and proton pump inhibitor combination in the treatment of gastrointestinal disorders
BRPI0621832A2 (pt) 2006-07-05 2013-03-19 Lupin Ltd processo para a preparaÇço de enantiâmeros oticamente puros ou oticamente enriquecidos de compostos de sulfàxido
RU2467747C2 (ru) 2006-07-25 2012-11-27 Векта Лтд. Композиции и способы для ингибирования секреции желудочной кислоты с использованием производных малых дикарбоновых кислот в сочетании с ppi
US20100317689A1 (en) * 2006-09-19 2010-12-16 Garst Michael E Prodrugs of proton pump inhibitors including the 1h-imidazo[4,5-b] pyridine moiety
CA2665226C (en) 2006-10-05 2014-05-13 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
EP2486910A3 (en) 2006-10-27 2012-08-22 The Curators Of The University Of Missouri Multi-chambered apparatus comprising a dispenser head
US20090124623A1 (en) * 2006-11-13 2009-05-14 Christopher Lademacher Methods for preserving and/or increasing renal function using xanthine oxidoreductase inhibitors
KR20160031040A (ko) * 2006-11-13 2016-03-21 다케다 파마슈티칼스 유에스에이, 인코포레이티드 크산틴 옥시도리덕타아제 억제제를 사용하여 신장 기능을 보존하는 방법
EP1947099A1 (en) 2007-01-18 2008-07-23 LEK Pharmaceuticals D.D. Process for solvent removal from omeprazole salts
CA2675443A1 (en) * 2007-01-19 2008-07-24 Takeda Pharmaceuticals North America, Inc. Methods for preventing or reducing the number of gout flares using xanthine oxidoreductase inhibitors and anti-inflammatory agents
EP2114919A2 (en) * 2007-01-31 2009-11-11 Krka Tovarna Zdravil, D.D., Novo Mesto Process for the preparation of optically pure omeprazole via salt formation with a chiral amine or treatment with an entiomer converting enzyme and chromatographic seperation
US20080194307A1 (en) * 2007-02-13 2008-08-14 Jeff Sanger Sports-based game of chance
CA2678702A1 (en) 2007-02-21 2008-08-28 Cipla Limited Process for the preparation of esomeprazole magnesium dihydrate
KR101303813B1 (ko) * 2007-04-16 2013-09-04 에스케이케미칼주식회사 라세믹 오메프라졸로부터 에스오메프라졸의 개선된제조방법
EP2000468A1 (en) * 2007-05-09 2008-12-10 Dr. Reddy's Laboratories Ltd. Esomeprazole salts and processes for preparation thereof
EP2152691B1 (en) * 2007-06-07 2011-11-23 Aurobindo Pharma Limited An improved process for preparing an optically active proton pump inhibitor
CN101323609B (zh) * 2007-06-15 2013-05-01 成都福瑞生物工程有限公司 不对称氧化硫醚成亚砜合成对映体含量高的苯并咪唑衍生物的方法
DK2106397T3 (da) 2007-09-25 2012-01-30 Hetero Drugs Ltd Fremgangsmåde til fremstilling af enantiomer-ren esomeprazol
US8106210B2 (en) 2007-10-08 2012-01-31 Hetero Drugs Limited Polymorphs of esomeprazole salts
FR2925899B1 (fr) * 2007-12-27 2012-12-21 Sidem Pharma Sa Procede de preparation enantioselective de sulfoxydes.
EP2252274A4 (en) 2008-02-20 2011-05-11 Univ Missouri COMPOSITION COMPRISING A COMBINATION OF OMEPRAZOLE AND LANSOPRAZOLE, AND A BUFFER AGENT, AND METHODS OF USING THE SAME
WO2009137648A1 (en) * 2008-05-09 2009-11-12 Aptapharma, Inc. Multilayer proton pump inhibitor tablets
US20090280173A1 (en) * 2008-05-09 2009-11-12 Ishwar Chauhan Multilayer Omeprazole Tablets
WO2009145368A1 (en) * 2008-05-27 2009-12-03 Sk Chemicals Co., Ltd. Improved preparing method of (s)-omeprazole from omeprazole racemate using optical resolution agent
EP2143722A1 (en) * 2008-07-09 2010-01-13 Lek Pharmaceuticals D.D. Process for preparation of esomeprazole sodium of high chemical purity and new forms of esomeprazole sodium
EP2147918A1 (en) 2008-07-21 2010-01-27 LEK Pharmaceuticals D.D. Process for the preparation of S-omeprazole magnesium in a stable form
CA2736547C (en) 2008-09-09 2016-11-01 Pozen Inc. Method for delivering a pharmaceutical composition to patient in need thereof
EP2264024A1 (en) 2008-10-14 2010-12-22 LEK Pharmaceuticals d.d. Process for the preparation of enantiomerically enriched proton pump inhibitors
WO2010058409A2 (en) 2008-11-18 2010-05-27 Hetero Research Foundation Optical purification of esomeprazole
US20100311756A1 (en) * 2009-01-22 2010-12-09 Takeda Pharmaceuticals North America, Inc. Methods for delaying the progression of at least one of cardiac hypertrophy, cardiac remodeling or left ventricular function or the onset of heart failure in subjects in need of treatment thereof
WO2010097583A1 (en) 2009-02-24 2010-09-02 Cipla Limited Esomeprazole potassium polymorph and its preparation
AU2010263304A1 (en) 2009-06-25 2012-02-02 Astrazeneca Ab Method for treating a patient at risk for developing an NSAID-associated ulcer
EA021112B1 (ru) * 2009-06-25 2015-04-30 Поузен Инк. Способ лечения боли и/или воспаления у пациента, нуждающегося в аспириновой терапии
EP2319504A1 (en) 2009-11-07 2011-05-11 Laboratorios Del. Dr. Esteve, S.A. Pharmaceutical solid dosage form
US8748619B2 (en) 2009-11-12 2014-06-10 Hetero Research Foundation Process for the resolution of omeprazole
WO2011080500A2 (en) 2009-12-29 2011-07-07 Orexo Ab New pharmaceutical dosage form for the treatment of gastric acid-related disorders
WO2011080501A2 (en) 2009-12-29 2011-07-07 Orexo Ab New pharmaceutical dosage form for the treatment of gastric acid-related disorders
WO2011080502A2 (en) 2009-12-29 2011-07-07 Orexo Ab New pharmaceutical dosage form for the treatment of gastric acid-related disorders
EP2345408A3 (en) 2010-01-08 2012-02-29 Dr. Reddy's Laboratories Ltd. Acid labile drug formulations
CA2789298A1 (en) 2010-02-12 2011-08-18 Esteve Quimica, S.A. Preparation process of the sodium salt of esomeprazole
US20110207779A1 (en) * 2010-02-25 2011-08-25 Glenmark Generics Ltd Process for the preparation of esomeprazole magnesium
RU2013109380A (ru) 2010-09-10 2014-10-20 Такеда Фармасьютикалс Ю.С.А.,Инк. Способ сопутствующей терапии с применением теофиллина и фебуксостата
CN102816149B (zh) * 2011-06-10 2015-05-13 上海汇伦生命科技有限公司 一种高对映选择性合成(s)-奥美拉唑及其盐的制备方法
CN102807561A (zh) * 2011-06-21 2012-12-05 寿光富康制药有限公司 S-奥美拉唑铝盐及其制备方法和应用
CN102850323A (zh) * 2011-06-30 2013-01-02 秦引林 一种埃索美拉唑钠的精制方法
CN102321071B (zh) * 2011-07-20 2013-01-23 江苏奥赛康药业股份有限公司 一种高纯度埃索美拉唑钠的工业化生产方法
CN104844577A (zh) * 2011-07-31 2015-08-19 连云港润众制药有限公司 埃索美拉唑镁的晶型
WO2013081566A1 (en) 2011-11-25 2013-06-06 Mahmut Bilgic A formulation comprising benzimidazole
EP2601947A1 (en) 2011-12-05 2013-06-12 Abo Bakr Mohammed Ali Al-Mehdar Fixed-dose combination for treatment of helicobacter pylori associated diseases
SG11201402796SA (en) 2011-12-16 2014-06-27 Atopix Therapeutics Ltd Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
MX2014007935A (es) 2011-12-28 2014-11-14 Pozen Inc Composiciones y metodos mejorados para el suministro de omeprazol y de acido acetilsalicilico.
CN104203938A (zh) 2012-01-21 2014-12-10 朱比兰特生命科学有限公司 用于制备2-吡啶基甲基亚硫酰基苯并咪唑、它们的类似物和光学活性对映体的方法
CN103420978A (zh) * 2012-05-15 2013-12-04 上海医药工业研究院 一种苯并咪唑类化合物的镁盐的制备方法
CN102657622A (zh) * 2012-05-17 2012-09-12 康普药业股份有限公司 一种含有埃索美拉唑钠的冻干粉针剂的制备工艺
CN102964335B (zh) * 2012-11-13 2014-06-25 凌元敏 一种埃索美拉唑钠化合物及其制备方法和用途
CN103159737B (zh) * 2013-04-12 2014-03-19 四川省惠达药业有限公司 一种埃索美拉唑钠化合物及药物组合物
EP3065720A1 (en) 2013-11-04 2016-09-14 Capsugel Belgium NV Methods and systems for improved bioavailability of active pharmaceutical ingredients including esomeprazole
EP2929885A1 (en) 2014-04-11 2015-10-14 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmaceutical combinations of rivaroxaban and proton pump inhibitors
US10130618B2 (en) 2014-04-11 2018-11-20 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical combinations of dabigatran and proton pump inhibitors
CN104045627A (zh) * 2014-05-21 2014-09-17 丽珠医药集团股份有限公司 一种奥美拉唑纯化方法
CN104530003A (zh) * 2014-06-10 2015-04-22 广东东阳光药业有限公司 吡啶甲基亚磺酰基-1h-苯并咪唑类化合物的盐的制备方法
EP2980086B1 (en) 2014-07-29 2016-06-15 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Efficient process for the preparation of esomeprazole (S)-binol complex
EP3239146A4 (en) 2014-12-26 2018-05-30 The University of Tokyo Method for producing proton pump inhibitor compound having optical activity
ES2615637T3 (es) 2015-03-06 2017-06-07 F.I.S.- Fabbrica Italiana Sintetici S.P.A. Procedimiento mejorado para la purificación óptica del esomeprazol
US10736855B2 (en) 2016-02-25 2020-08-11 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
CN105924430A (zh) * 2016-06-27 2016-09-07 杭州富阳伟文环保科技有限公司 一种埃索美拉唑钠的精制方法
WO2018191210A1 (en) * 2017-04-11 2018-10-18 Mclaughlin Gormley King Company Sabadilla oil and uses thereof
CN108409714A (zh) * 2018-03-29 2018-08-17 成都通德药业有限公司 埃索美拉唑、埃索美拉唑盐及埃索美拉唑镁的制备方法
CN114364371A (zh) * 2019-07-16 2022-04-15 金德雷德生物科学股份有限公司 马科动物埃索美拉唑配制品及其用途
US20220306593A1 (en) 2019-08-29 2022-09-29 Tokyo University Of Science Foundation Method for preparing enantiomer of sulfoxide compound, and system for preparing enantiomer
RU2726320C1 (ru) * 2020-02-09 2020-07-13 Федеральное государственное бюджетное образовательное учреждение высшего образования "Кемеровский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО КемГМУ) Способ определения примесных компонентов омепразола
WO2024075017A1 (en) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition of aortic valve calcification

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
US4636085A (en) * 1982-03-16 1987-01-13 Mapro Inc. Apparatus for removing volatiles from plastic materials delivered to an extrusion or injection molding machine
SE8204879D0 (sv) * 1982-08-26 1982-08-26 Haessle Ab Novel chemical intermediates
SE8301182D0 (sv) 1983-03-04 1983-03-04 Haessle Ab Novel compounds
US4445708A (en) * 1983-05-09 1984-05-01 General Motors Corporation Energy absorbing steering column for vehicles
SE8403179D0 (sv) * 1984-06-13 1984-06-13 Haessle Ab New compounds
IL75400A (en) * 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
CA1327010C (en) * 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
GB2189699A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US5075323A (en) * 1988-08-24 1991-12-24 Aktiebolaget Hassle Compounds including omeprazole in the treatment of glaucoma
DE4035455A1 (de) 1990-11-08 1992-05-14 Byk Gulden Lomberg Chem Fab Enantiomerentrennung
US5232706A (en) * 1990-12-31 1993-08-03 Esteve Quimica, S.A. Oral pharmaceutical preparation containing omeprazol
CA2161256C (en) * 1993-04-27 2004-06-29 Nancy M. Gray Methods and compositions for treating gastric disorders using optically pure (-) pantoprazole
US5877192A (en) * 1993-05-28 1999-03-02 Astra Aktiebolag Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
US6875872B1 (en) * 1993-05-28 2005-04-05 Astrazeneca Compounds
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
SE9302396D0 (sv) * 1993-07-09 1993-07-09 Ab Astra A novel compound form
EP0723436B1 (en) * 1994-07-08 2001-09-26 AstraZeneca AB Multiple unit tableted dosage form i
SE504459C2 (sv) * 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
SE508669C2 (sv) * 1996-04-26 1998-10-26 Astra Ab Nytt förfarande
SE510650C2 (sv) * 1997-05-30 1999-06-14 Astra Ab Ny förening
SE9704183D0 (sv) * 1997-11-14 1997-11-14 Astra Ab New process
SE9900274D0 (sv) * 1999-01-28 1999-01-28 Astra Ab New compound

Also Published As

Publication number Publication date
WO1994027988A1 (en) 1994-12-08
SI22752A (sl) 2009-10-31
US20080312449A1 (en) 2008-12-18
EP1020461A2 (en) 2000-07-19
ES2326404T3 (es) 2009-10-09
HK1028044A1 (en) 2001-02-02
DZ1785A1 (fr) 2002-02-17
DK1020461T3 (da) 2009-08-10
EP1020460A3 (en) 2003-10-15
JP2004043493A (ja) 2004-02-12
CN1107503C (zh) 2003-05-07
ES2326405T3 (es) 2009-10-09
HUT71888A (en) 1996-02-28
YU49065B (sh) 2003-08-29
SA05260103B1 (ar) 2010-01-31
TW389761B (en) 2000-05-11
EP1020461A3 (en) 2006-10-04
FI950377A (fi) 1995-01-27
NO2011009I1 (no) 2011-06-20
IS1854B (is) 2003-02-21
HK1028045A1 (en) 2001-02-02
DE69426254T2 (de) 2001-06-07
PT1020461E (pt) 2009-07-29
ES2099047T1 (es) 1997-05-16
DE69435220D1 (de) 2009-09-03
RU2137766C1 (ru) 1999-09-20
NO950263L (no) 1995-01-24
MA23210A1 (fr) 1994-12-31
JP4039999B2 (ja) 2008-01-30
LTIP1941A (en) 1994-12-27
PL178994B1 (pl) 2000-07-31
IL109684A0 (en) 1994-12-29
EP1020460B1 (en) 2009-07-22
EP0652872A1 (en) 1995-05-17
DE69426254D1 (de) 2000-12-14
SK10195A3 (en) 1995-09-13
CN1110477A (zh) 1995-10-18
JP3549111B2 (ja) 2004-08-04
CL2009000805A1 (es) 2009-08-21
AU676337B2 (en) 1997-03-06
US20100222591A1 (en) 2010-09-02
CN1259346A (zh) 2000-07-12
CA2139653A1 (en) 1994-12-08
HRP940307B1 (en) 2001-06-30
EP0652872B1 (en) 2000-11-08
JP2004043494A (ja) 2004-02-12
LT3287B (en) 1995-06-26
CZ287876B6 (cs) 2001-03-14
ES2099047T3 (es) 2001-03-01
YU31494A (sh) 1997-05-28
LV11034A (lv) 1996-02-20
JPH07509499A (ja) 1995-10-19
NZ266915A (en) 1996-10-28
NO307378B1 (no) 2000-03-27
NO950263D0 (no) 1995-01-24
FI20070002A (fi) 2007-01-02
EP1020461B2 (en) 2015-10-21
CN1055469C (zh) 2000-08-16
HU9500247D0 (en) 1995-03-28
FI117755B (fi) 2007-02-15
HU226824B1 (en) 2009-11-30
ES2326405T5 (es) 2016-02-15
CZ20295A3 (en) 1995-10-18
JP3959056B2 (ja) 2007-08-15
EP1020460A2 (en) 2000-07-19
CA2337581A1 (en) 1994-12-08
KR100337274B1 (ko) 2003-12-31
DE652872T1 (de) 1997-09-04
PL307261A1 (en) 1995-05-15
SG49283A1 (en) 1998-05-18
DK1020460T3 (da) 2009-08-10
SI22752B (sl) 2010-01-29
PT652872E (pt) 2001-04-30
DK1020461T4 (en) 2016-02-15
ATE197452T1 (de) 2000-11-11
EP1020461B1 (en) 2009-07-22
ZA943557B (en) 1995-04-11
IL109684A (en) 2002-05-23
US6143771A (en) 2000-11-07
FI950377A0 (fi) 1995-01-27
US5714504A (en) 1998-02-03
PT1020460E (pt) 2009-07-29
DK0652872T3 (da) 2001-03-05
EE03157B1 (et) 1999-02-15
KR950702553A (ko) 1995-07-29
CA2139653C (en) 2001-07-10
LU91870I2 (fr) 2011-11-21
RU95105587A (ru) 1996-10-27
MY121192A (en) 2006-01-28
SI9420002A (en) 1995-08-31
HRP940307A2 (en) 1996-12-31
SA94140756B1 (ar) 2006-05-20
SE9301830D0 (sv) 1993-05-28
LV11034B (en) 1996-10-20
HK1008330A1 (en) 1999-05-07
SI9420002B (sl) 2009-12-31
US5693818A (en) 1997-12-02
CY2224B1 (en) 2003-04-18
TNSN94058A1 (fr) 1995-04-25
AU6902494A (en) 1994-12-20
SK282524B6 (sk) 2002-10-08
UA60289C2 (uk) 2003-10-15
DE69435221D1 (de) 2009-09-03
GR970300012T1 (en) 1997-05-31
GR3035365T3 (en) 2001-05-31

Similar Documents

Publication Publication Date Title
IS4161A (is) Aðferð til að útbúa ljósfræðilega hrein Na+, Mg2+, Li+, K+ eða Ca2+ sölt (-)-5-metoxý-2-[[(4-metoxý-3,5-dímetýl-2-pýridínýl)metýl]súlfinýl]-1H-bensimídasóls og milliefnasamband.
HU901539D0 (en) Process for the production of antibacterial medical preparations containing omeprazole
NO20016087D0 (no) Benzimidazolforbindelsekrystall